Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Smart engineered and naturally derived nanovesicles, capable of targeting specific tissues and cells and delivering bioactive molecules and drugs into them, are becoming important drug delivery systems. Liposomes stand out among different types of self-assembled nanovesicles, because of their amphiphilicity and non-toxic nature. By modifying their surfaces, liposomes can become stimulus-responsive, releasing their cargo on demand. Recently, the recognized role of exosomes in cell-cell communication and their ability to diffuse through tissues to find target cells have led to an increase in their usage as smart delivery systems. Moreover, engineering “smarter” delivery systems can be done by creating hybrid exosome-liposome nanocarriers via membrane fusion. These systems can be loaded in naturally derived hydrogels to achieve sustained and controlled drug delivery. Here, the focus is on evaluating the smart behavior of liposomes and exosomes, the fabrication of hybrid exosome-liposome nanovesicles, and the controlled delivery and routes of administration of a hydrogel matrix for drug delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“Doxil®, a typical PEGylated liposome encapsulating the chemotherapy drug doxorubicin, was the first nanodrug approved by the Food and Drug Administration (FDA) in 1995 [44].”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“Bangham noticed that phospholipids formed a closed bilayer upon contact with water [24,25].”
BackgroundExosome secreted by MSC reduces myocardial ischemia/reperfusion injury
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., Salto-Tellez, M., Timmers, L., Lee, C. N., El Oakley, R. M., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2009.12.003 · Cited by 2,215
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600 · cited 2×
“Hydrophobic molecules are entrapped in the lipid bilayer with a higher efficiency than the entrapment of hydrophilic molecules in the aqueous core, due to the lower volume of hydration in the liposome core [26].”
BackgroundStructural and Rheological Properties of Methacrylamide Modified Gelatin Hydrogels
Van Den Bulcke, A. I., Bogdanov, B., De Rooze, N., Schacht, E. H., Cornelissen, M., & Berghmans, H. (2000) · Biomacromolecules · doi:10.1021/bm990017d · Cited by 1,536
25th Anniversary Article: Rational Design and Applications of Hydrogels in Regenerative Medicine
Annabi, N., Tamayol, A., Uquillas, J. A., Akbari, M., Bertassoni, L. E., Cha, C., Camci‐Unal, G., Dokmeci, M. R., Peppas, N. A., & Khademhosseini, A. (2014) · Advanced Materials · doi:10.1002/adma.201303233 · Cited by 1,409
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406 · cited 1×
“Some challenges that exist include higher tear dilution and turnover rate, toxicity due to high dosage, and cataracts, among others [133].”
BackgroundAnselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 2×
“However, nanoparticles seem to have the possibility to achieve desired therapeutic effects [140].”
BackgroundEngineering hybrid exosomes by membrane fusion with liposomes
Sato, Y. T., Umezaki, K., Sawada, S., Mukai, S.-A., Sasaki, Y., Harada, N., Shiku, H., & Akiyoshi, K. (2016) · Scientific Reports · doi:10.1038/srep21933 · Cited by 744 · cited 2×
“The result of the study demonstrated a new way to hybridize exosomes into a biological nanocarrier, which could be used to transport exogenous hydrophobic lipids, as well as hydrophilic cargos to recipient cells via membrane fusion method [7].”
BackgroundMethodJohnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704
Adapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663 · cited 2×
“Liposomes’ resemblance to biomembranes enables superior biocompatibility and safety over other polymeric and metal-based nanoparticles, as well as the ability to deliver lipid-soluble and water-soluble molecules at the same time [2,3].”
BackgroundExosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs
Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., & Tan, J. (2018) · Advanced Science · doi:10.1002/advs.201700611 · Cited by 625
Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery
Antimisiaris, S. G., Mourtas, S., & Marazioti, A. (2018) · doi:10.20944/preprints201810.0507.v1 · Cited by 605
Wang, P., Wang, H., Huang, Q., Peng, C., Yao, L., Chen, H., Qiu, Z., Wu, Y., Wang, L., & Chen, W. (2019) · Theranostics · doi:10.7150/thno.30716 · Cited by 494
Turturici, G., Tinnirello, R., Sconzo, G., & Geraci, F. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00228.2013 · Cited by 483
Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481 · cited 2×
“Exosomes differ from other extracellular vesicles with their unique biogenesis pathways, lipid compositions, and cargo that they can carry [76].”
BackgroundMacrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery
Rayamajhi, S., Nguyen, T. D. T., Marasini, R., & Aryal, S. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.054 · Cited by 429
The "Stealth" Liposome: A Prototypical Biomaterial
Lasic, D. D., & Needham, D. (1995) · Chemical Reviews · doi:10.1021/cr00040a001 · Cited by 416
Therapeutic applications of hydrogels in oral drug delivery
Sharpe, L. A., Daily, A. M., Horava, S. D., & Peppas, N. A. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.902047 · Cited by 354
Hasan, M., Elkhoury, K., Kahn, C. J. F., Arab-Tehrany, E., & Linder, M. (2019) · Molecules · doi:10.3390/molecules24102023 · Cited by 133
Self-citationNanoliposomes from Agro-Resources as Promising Delivery Systems for Chondrocytes
Bianchi, A., Velot, É., Kempf, H., Elkhoury, K., Sanchez-Gonzalez, L., Linder, M., Kahn, C., & Arab-Tehrany, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103436 · Cited by 23
Self-citation
Cited by
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“Liposomes can be classified as conventional, PEGylated/stealth, or ligand-targeted based on the characteristics of their surface [202].”
BackgroundSelf-citationIsolation and characterization of exosomes for cancer research
Zhu, L., Sun, H.-T., Wang, S., Huang, S.-L., Zheng, Y., Wang, C.-Q., Hu, B.-Y., Qin, W., Zou, T.-T., Fu, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00987-y · Cited by 520
Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems
Delgado-Pujol, E. J., Martínez, G., Casado-Jurado, D., Vázquez, J., León-Barberena, J., Rodríguez-Lucena, D., Torres, Y., Alcudia, A., & Begines, B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020215 · Cited by 216
Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants
Alghuthaymi, M. A., Ahmad, A., Khan, Z., Khan, S. H., Ahmed, F. K., Faiz, S., Nepovimova, E., Kuča, K., & Abd-Elsalam, K. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147456 · Cited by 83
Current advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles
Belhadj, Z., Qie, Y., Carney, R. P., Li, Y., & Nie, G. (2023) · BMEMat · doi:10.1002/bmm2.12018 · Cited by 79
Metadata
- Authors
- Elkhoury, K., Koçak, P., Kang, A., Arab-Tehrany, E., Ellis Ward, J., & Shin, S. R.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-09-07
- Volume
- 12
- Issue
- 9
- Pages
- 849
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3083256994
- Cited by
- 128
- References
- 25
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.